pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.89 [0.77, 1.02]< 10%1 study (1/-)94.8 %NAnot evaluable crucial-
objective responses (ORR) 7.28 [3.12, 17.00]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 1.86 [1.47, 2.35]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE (grade 3-4) 1.16 [0.92, 1.45]< 10%1 study (1/-)10.3 %NAnot evaluable non important-
AE leading to death (grade 5) 1.28 [0.78, 2.13]< 10%1 study (1/-)16.5 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 2.62 [1.36, 5.04]< 10%1 study (1/-)0.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons